MCI conversion to dementia and the APOE genotype: A prediction study with FDG-PET

Neurology

Volumn 63, Issue 12, 2004, Pages 2332-2340

  Mosconi, L ^a,e   Perani, D ^b,c   Sorbi, S ^a   Herholz, K ^f   Nacmias, B ^a   Holthoff, V ^h   Salmon, E ⁱ   Baron, J C ^g   De Cristofaro, M T R ^a   Padovani, A ^d   Borroni, B ^d,g   Franceschi, M ^b   Bracco, L ^a   Pupi, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^g UNIVERSITY OF COLOGNE   (Germany)

^h UNIVERSITY OF LIÈGE   (Belgium)

ⁱ UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; FRONTAL CORTEX; GENOTYPE; GLUCOSE METABOLISM; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; MALE; METABOLIC RATE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; OUTCOMES RESEARCH; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TEMPORAL CORTEX;

EID: 19944406770     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000147469.18313.3B     Document Type: Article

References (46)

1. Luis CA, Loewenstein DA, Acevedo A, Barker WW, Duara R. Mild cognitive impairment. Directions for future research. Neurology 2003; 61:438-444.
2. Petersen RC, Doody R, Kurz A. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
3. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology 1991;41:1006-1009.
4. DeCarli C. Mild cognitive impairment: diagnosis, prognosis, aetiology, and treatment. Lancet Neurol 2003;2:15-21.
5. Larrieu A, Letenneur L, Orgogozo J, et al. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002;59:1594-1599.
6. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-923.
7. Petersen RC, Smith G, Ivnik R, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995;273:1274-1278.
8. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661-665.
9. DeCarli C, Miller BL, Swan GE, Reed T, Wolf PA, Carmelli D. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol 2001;58:643-647.
10. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:6037-6042.
11. Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Converting brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:3334-3339.
12. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98: 10966-10971.
13. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage 2002;17:302-316.
14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
15. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
16. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
17. Sorbi S, Nacmias B, Forleo P, et al. APOE allele frequencies in Italian sporadic and familial Alzheimer's disease. Neurosci Lett 1994;177:100-102.
18. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179-186.
19. Lezak MD. Neuropsychological assessment. 2nd ed. New York: Oxford University Press, 1983.
20. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain: 3-dimensional proportional system-an approach to cerebral imaging. New York: Thieme Medical, 1988.
21. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Map 1995;2:189-210.
22. Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC. Characterising brain images with the general linear model. In: Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Mazziotta JC, eds. Human brain function. San Diego: Academic Press, 1997:59-84.
23. Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC. A unified statistical approach for determining significant signals in images of cerebral activation. Hum Brain Map 1996;4:58-73.
24. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
25. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998;50:1563-1571.
26. Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 2000;41:1155-1162.
27. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imag 2003;30:1104-1113.
28. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003;54:343-351.
29. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001;12:851-855.
30. Chetelat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-1377.
31. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: Wiley, 1973.
32. Desgranges B, Baron JC, de la Sayette V, et al. The neural substrates of memory systems impairment in Alzheimer's disease: a PET study of resting brain glucose utilization. Brain 1998;121:611-631.
33. Hirono N, Hashimoto M, Yasuda M, et al. The effect of APOE E4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002;58:743-750.
34. Mosconi L, Nacmias B, Sorbi S, et al. Brain metabolic decreases related to the dose of the APOE E4 allele in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:370-376.
35. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002;159:738-745.
36. Terry RD, DeTeresa R, Hansen LA. Neocortical cell counts in normal human adult aging. Ann Neurol 1987;21:530-539.
37. Mosconi L, Sorbi S, Nacmias B, et al. Age and APOE genotype interaction in Alzheimer's disease. An FDG-PET study. Psychiatr Res Neuroimag 2004;130:141-150.
38. Berg L, McKeel DW Jr, Miller JP. Clinicopathological studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998;55:326-335.
39. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003;84:1215-1236.
40. Herholz K, Nordberg A, Salmon E, et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:494-504.
41. Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
42. Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998;50:1585-1593.
43. Jack CR Jr, Petersen RC, Xu YC, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999;52:1397-1403.
44. De Santi S, deLeon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-539.
45. Reiman EM, Uecker A, Caselli RJ, et al. Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol 1998;44:288-291.
46. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, 1988:21-23.